Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

• Published in: Annals of oncology Vol. 31; no. 1; pp. 17 - 29
• Main Authors: Zucca, E., Arcaini, L., Buske, C., Johnson, P.W., Ponzoni, M., Raderer, M., Ricardi, U., Salar, A., Stamatopoulos, K., Thieblemont, C., Wotherspoon, A., Ladetto, M.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2020
• Subjects: clinical practice guidelines; extranodal marginal zone lymphoma (EMZL); Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone - diagnosis; Lymphoma, B-Cell, Marginal Zone - epidemiology; Lymphoma, B-Cell, Marginal Zone - therapy; marginal zone B-cell lymphoma (MZL); mucosa-associated lymphoid tissue (MALT); nodal marginal zone lymphoma (NMZL); splenic marginal zone lymphoma (SMZL); extranodal marginal zone lymphoma (EMZL); nodal marginal zone lymphoma (NMZL); clinical practice guidelines; splenic marginal zone lymphoma (SMZL); marginal zone B-cell lymphoma (MZL); mucosa-associated lymphoid tissue (MALT)
• ISSN: 0923-7534; 1569-8041; 1569-8041
• DOI: 10.1016/j.annonc.2019.10.010

•This updated ESMO Clinical Practice Guideline provides key recommendations on the management of marginal zone lymphomas.•Authorship includes a multidisciplinary group of experts from different institutions and countries in Europe and abroad.•A summary of recommendations is provided, including levels of evidence and grades of recommendation where applicable.•The distinct disease entities (i.e. extranodal, nodal and splenic marginal zone lymphomas) are discussed separately.•Organ-specific peculiarities are addressed in the recommendations for extranodal marginal zone lymphomas (MALT lymphomas).